Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Free Cash Flow (2016 - 2025)

CorMedix's Free Cash Flow history spans 13 years, with the latest figure at $92.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 1748.72% year-over-year to $92.7 million; the TTM value through Dec 2025 reached $172.8 million, up 440.59%, while the annual FY2025 figure was $172.8 million, 440.59% up from the prior year.
  • Free Cash Flow for Q4 2025 was $92.7 million at CorMedix, up from $30.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $92.7 million in Q4 2025 and bottomed at -$17.4 million in Q1 2024.
  • The 5-year median for Free Cash Flow is -$6.3 million (2021), against an average of $3.8 million.
  • The largest annual shift saw Free Cash Flow plummeted 308.37% in 2021 before it surged 1748.72% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$6.5 million in 2021, then increased by 3.3% to -$6.3 million in 2022, then tumbled by 65.65% to -$10.4 million in 2023, then soared by 45.96% to -$5.6 million in 2024, then soared by 1748.72% to $92.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Free Cash Flow are $92.7 million (Q4 2025), $30.4 million (Q3 2025), and $30.0 million (Q2 2025).